Intraglomerular inhibition maintains mitral cell response contrast across input frequencies.

J Neurophysiol

Department of Anatomy and Neurobiology, Program in Neuroscience, University of Maryland School of Medicine, Baltimore, Maryland.

Published: November 2013

Odor signals are transmitted to the olfactory bulb by olfactory nerve (ON) synapses onto mitral/tufted cells (MTCs) and external tufted cells (ETCs); ETCs provide additional feed-forward excitation to MTCs. Both are strongly regulated by intraglomerular inhibition that can last up to 1 s and, when blocked, dramatically increases ON-evoked MC spiking. Intraglomerular inhibition thus limits the magnitude and duration of MC spike responses to sensory input. In vivo, sensory input is repetitive, dictated by sniffing rates from 1 to 8 Hz, potentially summing intraglomerular inhibition. To investigate this, we recorded MTC responses to 1- to 8-Hz ON stimulation in slices. Inhibitory postsynaptic current area (charge) following each ON stimulation was unchanged from 1 to 5 Hz and modestly paired-pulse attenuated at 8 Hz, suggesting there is no summation and only limited decrement at the highest input frequencies. Next, we investigated frequency independence of intraglomerular inhibition on MC spiking. MCs respond to single ON shocks with an initial spike burst followed by reduced spiking decaying to baseline. Upon repetitive ON stimulation peak spiking is identical across input frequencies but the ratio of peak-to-minimum rate before the stimulus (max-min) diminishes from 30:1 at 1 Hz to 15:1 at 8 Hz. When intraglomerular inhibition is selectively blocked, peak spike rate is unchanged but trough spiking increases markedly decreasing max-min firing ratios from 30:1 at 1 Hz to 2:1 at 8 Hz. Together, these results suggest intraglomerular inhibition is relatively frequency independent and can "sharpen" MC responses to input across the range of frequencies. This suggests that glomerular circuits can maintain "contrast" in MC encoding during sniff-sampled inputs.

Download full-text PDF

Source
http://www.ncbi.nlm.nih.gov/pmc/articles/PMC3841927PMC
http://dx.doi.org/10.1152/jn.00023.2013DOI Listing

Publication Analysis

Top Keywords

intraglomerular inhibition
28
input frequencies
12
sensory input
8
intraglomerular
7
input
6
inhibition
6
spiking
5
inhibition maintains
4
maintains mitral
4
mitral cell
4

Similar Publications

Serum symmetric dimethylarginine concentrations in enalapril- or telmisartan-treated dogs with proteinuric chronic kidney disease.

Front Vet Sci

December 2024

Department of Small Animal Medicine and Surgery, College of Veterinary Medicine, University of Georgia, Athens, GA, United States.

Introduction: Renin-angiotensin-aldosterone system inhibition (RAASi) reduces intraglomerular pressure and is a standard therapy for dogs with proteinuric chronic kidney disease (CKD). RAASi can acutely decrease glomerular filtration rate (GFR); however, its effects on the marker of GFR serum symmetric dimethylarginine (SDMA) concentration in dogs have not been specifically evaluated. The objective of this study was to evaluate changes, relative to pretreatment values, in serum SDMA concentrations in dogs with proteinuric CKD receiving RAASi therapy.

View Article and Find Full Text PDF
Article Synopsis
  • Recent research shows that SLC5A2/SGLT2 inhibitors, like empagliflozin, offer kidney protection in non-diabetic chronic kidney disease (CKD) without clear signs of albuminuria, yet the mechanism of this effect remains unclear.
  • The study used various mouse models, including those with obesity and kidney injury, and found that empagliflozin reduced harmful effects like lipotoxicity, inflammation, and fibrosis in kidney tubules by lowering intraglomerular pressure.
  • Empagliflozin also decreased albumin reabsorption, improved autophagic processes, and lessened the risk of kidney injury, suggesting that enhancing autophagy is key to the protective effects
View Article and Find Full Text PDF

B cell targeting in IgA nephropathy.

Nephrology (Carlton)

September 2024

Department of Nephrology, Juntendo University Faculty of Medicine, Tokyo, Japan.

Article Synopsis
  • The multi-hit theory explains that IgA nephropathy (IgAN) starts with galactose-deficient IgA1 (GdIgA1), leading to chronic inflammation and progressive kidney damage due to complement pathway activation and increased pressure within the glomeruli.
  • New treatments are emerging that target different stages of IgAN's pathophysiology, including drugs that regulate complement, block endothelin receptors, and inhibit glucose reabsorption in kidneys. Promising clinical trials are underway for therapies aimed at reducing GdIgA1 production by targeting specific B cells.
  • The production of nephrit
View Article and Find Full Text PDF

Diagnosing and Treating IgAN: Steroids, Budesonide, or Maybe Both?

Diagnostics (Basel)

February 2024

1st Department of Nephrology, Hippokration Hospital, School of Medicine, Aristotle University of Thessaloniki, 54642 Thessaloniki, Greece.

IgA nephropathy (IgAN), the most common primary glomerulonephritis worldwide, is characterized by a mesangial IgA deposit and a variety of histological lesions, as described by the Oxford classification system. Despite the well-described "four-hit hypothesis", there are still plenty of less or undescribed mechanisms that participate in the disease pathogenesis, such as B-cell priming, which seems to be initiated by different antigens in the intestinal microbiota. Diagnosis of the disease is currently based on kidney biopsy findings, as the sensitivity and specificity of the many serum and urinary biomarkers described so far do not seem to have diagnostic accuracy.

View Article and Find Full Text PDF
Article Synopsis
  • - A 75-year-old woman with colon cancer developed massive proteinuria after treatment with FOLFIRI and bevacizumab, leading to the discontinuation of only bevacizumab, which initially improved her condition.
  • - More than six months later, she experienced a recurrence of proteinuria and declining kidney function, with a biopsy revealing damage due to chronic endothelial cell issues thought to be related to bevacizumab and other chemotherapy drugs.
  • - Despite attempts to manage her condition through diet and antihypertensive therapy, the patient's ability to continue chemotherapy suffered, indicating that careful monitoring and management of related health issues are essential in cancer treatments to prevent renal complications.
View Article and Find Full Text PDF

Want AI Summaries of new PubMed Abstracts delivered to your In-box?

Enter search terms and have AI summaries delivered each week - change queries or unsubscribe any time!